

Application Serial No. 10/005,646
Attorney Docket No. 51835AUSM1
Response to Office Action of 17 March 2004

40. (Once Amended) The method of Claim 36, wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 208 of human FGF-9 as set forth in Fig. 3 (SEQ ID NO: 5), and wherein said polypeptide has FGF activity.

41. (Once Amended) The method of Claim 37, wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 208 of human FGF-9 as set forth in Fig. 3 (SEQ ID NO: 5), and wherein said polypeptide has FGF activity.

In the Specification:

Please insert the following section entitled "BRIEF DESCRIPTION OF THE DRAWINGS" after line 10, page 1:

--- BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the nucleotide and amino acid sequence of FGF-20. (SEQ ID NOS. 1 and 2)

Fig. 2 shows the nucleotide and amino acid sequence of FGF-23. (SEQ ID NOS. 3 and 4)

Fig. 3 shows the aligned amino acid sequence of FGF-20 protein with known FGF-family members. xfgf-20 is from *Xenopus laevis*.

Fig. 4 shows oligodendrocyte proliferation. Fig. 4A shows the proliferation of oligodendrocytes. Fig. 4B shows that activity is abolished by boiling the protein.

Fig. 5 shows the effect of FGF-20 on N20.1 oligodendrocyte proliferation.

Fig. 6 shows the effect of FGFs on the proliferation of primary rat oligodendrocytes (PRO). Fig. 6A shows cells treated with FGF-2. Fig. 6B shows cells treated with FGF-20.

Fig. 7 shows the effect of FGFs on the survival/proliferation of a cell line of neuronal origin. Fig. 7A shows the effect of FGF-20. Fig. 7B shows the effect of FGF-2, FGF-9 and FGF-20.

Fig. 8 shows neurite outgrowth. Cultured PC12 cells are treated for 6 days with recombinant FGF-20 plus heparin (left panel) or heparin alone (right panel). Cells are fixed and stained for β III-tubulin, nuclei are imaged with 7-AAD. Neurite outgrowth is not observed in cells treated with heparin alone.

Fig. 9 shows that FGF-20 is a potent survival factor for cortical neurons. ---

Please delete the section entitled "BRIEF DESCRIPTION OF THE DRAWINGS", line 23, page 32 to line 14, page 33.

Please insert --- (SEQ ID NO: 2) --- following "Fig. 1", line 29, page 2.

Please insert --- (SEQ ID NO: 4) --- following "Fig. 2", line 30, page 2.

Please insert --- (SEQ ID NOS: 1 and 3, respectively) --- following "Figs. 1 and 2", line 5, page 7.

Please insert --- (SEQ ID NOS: 1 and 3, respectively) --- following "Figs. 1 and 2", line 16, page 9.

Please insert --- (SEQ ID NOS: 1 and 3, respectively) --- following "Figs. 1 and 2", line 26, page 10.